1.Early Goal Directed Sedation, a bridge to better clinical outcomes.
Chinese Medical Journal 2014;127(10):1969-1972
2.Dexmedetomidine-midazolam versus Sufentanil-midazolam for Awake Fiberoptic Nasotracheal Intubation: A Randomized Double-blind Study.
Cheng-Wen LI ; Yan-Dong LI ; Hai-Tao TIAN ; Xian-Gang KONG ; Kui CHEN
Chinese Medical Journal 2015;128(23):3143-3148
BACKGROUNDAwake fiberoptic intubation (AFOI) is usually performed in the management of the predicted difficult airway. The aim of this study was to evaluate the feasibility of dexmedetomidine with midazolam (DM) and sufentanil with midazolam (SM) for sedation for awake fiberoptic nasotracheal intubation.
METHODSFifty patients with limited mouth opening scheduled for AFOI were randomly assigned to two groups (n = 25 per group) by a computer-generated randomization schedule. All subjects received midazolam 0.02 mg/kg as premedication and airway topical anesthesia with a modified "spray-as-you-go" technique. Group DM received dexmedetomidine at a loading dose of 0.5 μg/kg over 10 min followed by a continuous infusion of 0.25 μg·kg-1·h-1, whereas Group SM received sufentanil at a loading dose of 0.2 μg/kg over 10 min followed by a continuous infusion of 0.1 μg·kg-1·h-1. As necessary, since the end of the administration of the loading dose of the study drug, an additional dose of midazolam 0.5 mg at 2-min intervals was given to achieve a modified Observers' Assessment of Alertness/Sedation of 2-3. The quality of intubation conditions and adverse events were observed.
RESULTSThe scores of ease of the AFOI procedure, patient's reaction during AFOI, coughing severity, tolerance after intubation, recall of the procedure and discomfort during the procedure were comparable in both groups (z = 0.572, 0.664, 1.297, 0.467, 0.895, and 0.188, respectively, P > 0.05). Hypoxic episodes similarly occurred in the two groups, but the first partial pressure of end-tidal CO2after intubation was higher in Group SM than that in Group DM (45.2 ± 4.2 mmHg vs. 42.2 ± 4.3 mmHg, t = 2.495, P < 0.05).
CONCLUSIONSBoth dexmedetomidine and sufentanil are effective as an adjuvant for AFOI under airway topical anesthesia combined with midazolam sedation, but respiratory depression is still a potential risk in the sufentanil regimen.
Adult ; Conscious Sedation ; methods ; Dexmedetomidine ; adverse effects ; therapeutic use ; Double-Blind Method ; Female ; Fiber Optic Technology ; methods ; Humans ; Hypnotics and Sedatives ; adverse effects ; therapeutic use ; Intubation, Intratracheal ; methods ; Male ; Midazolam ; adverse effects ; therapeutic use ; Middle Aged ; Sufentanil ; adverse effects ; therapeutic use ; Wakefulness
3.Effect of sequential sedation and analgesia in preventing delirium and withdrawal symptoms in children after ventilator weaning.
Wen-Hai YANG ; Zhi-Jun LAI ; Yan LI ; Ke-Ze MA
Chinese Journal of Contemporary Pediatrics 2022;24(7):748-752
OBJECTIVES:
To investigate the effect of sequential sedative and analgesic drugs in preventing delirium and withdrawal symptoms in children after ventilator weaning.
METHODS:
A retrospective analysis was performed on 61 children who were admitted and received mechanical ventilation support for ≥5 days in the Pediatric Intensive Care Unit of Dongguan Children's Hospital Affiliated to Guangdong Medical University from December 2019 to September 2021. The children were divided into a control group (30 children with no maintenance of analgesic and sedative drugs after ventilator weaning) and an observation group (31 children with sequential sedative and analgesic drugs maintained for 48 hours after ventilator weaning). The two groups were compared in terms of the Sophia Observation Withdrawal Symptoms Scale (SOS) score, the Pediatric Delirium Scale (PD) score, the Richmond Agitation-Sedation Scale (RASS) score, and the incidence rates of delirium or withdrawal symptoms at 24 and 72 hours after ventilator weaning.
RESULTS:
There was no significant difference in the incidence rate of delirium at 24 hours and 72 hours after ventilator weaning between the two groups (P>0.05). Compared with the control group, the observation group had significantly lower incidence rate of withdrawal symptoms and scores of SOS, PD, and RASS scales at 24 hours and 72 hours after ventilator weaning (P<0.01).
CONCLUSIONS
Sequential sedation and analgesia after ventilator weaning can reduce the incidence of withdrawal symptoms within 72 hours after ventilator weaning, but it cannot reduce the incidence rate of delirium.
Analgesia
;
Analgesics/therapeutic use*
;
Child
;
Delirium/prevention & control*
;
Humans
;
Hypnotics and Sedatives/therapeutic use*
;
Intensive Care Units, Pediatric
;
Pain
;
Prospective Studies
;
Respiration, Artificial/adverse effects*
;
Retrospective Studies
;
Substance Withdrawal Syndrome/prevention & control*
;
Ventilator Weaning
4.Zolpidem Use and Risk of Fracture in Elderly Insomnia Patients.
Dong Yoon KANG ; Soyoung PARK ; Chul Woo RHEE ; Ye Jee KIM ; Nam Kyong CHOI ; Joongyub LEE ; Byung Joo PARK
Journal of Preventive Medicine and Public Health 2012;45(4):219-226
OBJECTIVES: To evaluate the risk of fractures related with zolpidem in elderly insomnia patients. METHODS: Health claims data on the entire South Korean elderly population from January 2005 to June 2006 were extracted from the Health Insurance Review and Assessment Service database. We applied a case-crossover design. Cases were defined as insomnia patients who had a fracture diagnosis. We set the hazard period of 1 day length prior to the fracture date and four control periods of the same length at 5, 10, 15, and 20 weeks prior to the fracture date. Time independent confounding factors such as age, gender, lifestyle, cognitive function level, mobility, socioeconomic status, residential environment, and comorbidity could be controlled using the casecrossover design. Time dependent confounding factors, especially co-medication of patients during the study period, were adjusted by conditional logistic regression analysis. The odds ratios and their 95% confidence intervals (CIs) were estimated for the risk of fracture related to zolpidem. RESULTS: One thousand five hundred and eight cases of fracture were detected in insomnia patients during the study period. In our data, the use of zolpidem increased the risk of fracture significantly (adjusted odds ratio [aOR], 1.72; 95% CI, 1.37 to 2.16). However, the association between benzodiazepine hypnotics and the risk of fracture was not statistically significant (aOR, 1.00; 95% CI, 0.83 to 1.21). Likewise, the results were not statistically significant in stratified analysis with each benzodiazepine generic subgroup. CONCLUSIONS: Zolpidem could increase the risk of fracture in elderly insomnia patients. Therefore zolpidem should be prescribed carefully and the elderly should be provided with sufficient patient education.
Aged
;
Aged, 80 and over
;
Benzodiazepines/adverse effects/therapeutic use
;
Cross-Over Studies
;
Female
;
Fractures, Bone/chemically induced/*epidemiology
;
Humans
;
Hypnotics and Sedatives/adverse effects/therapeutic use
;
Male
;
Odds Ratio
;
Pyridines/*adverse effects/*therapeutic use
;
Republic of Korea/epidemiology
;
Risk Assessment
;
Risk Factors
;
Sleep Initiation and Maintenance Disorders/*drug therapy
5.Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients.
Helge MÜLLER ; Frank SEIFERT ; Juan-Manuel MALER ; Johannes KORNHUBER ; Wolfgang SPERLING
Singapore medical journal 2012;53(11):e228-30
The treatment of benzodiazepine withdrawal is difficult, and the search continues for substances that can reduce craving and the risk of relapse. Here, we report three cases of benzodiazepine addicts with histories of unsuccessful withdrawal attempts who experienced marked reductions in craving and improved relapse prognoses under add-on administration of agomelatine. These cases demonstrate a possible area of use for the antidepressant agomelatine in the treatment of benzodiazepine withdrawal and addiction. The extent to which this effect is due to the anti-craving effects of agomelatine, or its profile of receptor activation, should be further investigated in larger clinical and experimental studies.
Acetamides
;
therapeutic use
;
Adult
;
Antidepressive Agents
;
therapeutic use
;
Behavior, Addictive
;
Benzodiazepines
;
adverse effects
;
Female
;
Follow-Up Studies
;
Humans
;
Hypnotics and Sedatives
;
adverse effects
;
Lorazepam
;
adverse effects
;
Male
;
Middle Aged
;
Substance Withdrawal Syndrome
;
drug therapy
;
Substance-Related Disorders
;
drug therapy
;
Time Factors
;
Treatment Outcome
6.Effect of a Sleep Aid in Analgesia after Arthroscopic Rotator Cuff Repair.
Chul Hyun CHO ; Si Wook LEE ; Young Kuk LEE ; Hong Kwan SHIN ; Ilseon HWANG
Yonsei Medical Journal 2015;56(3):772-777
PURPOSE: The aim of this study was to evaluate the effects and safety of a sleep aid for postoperative analgesia in patients undergoing arthroscopic rotator cuff repair. MATERIALS AND METHODS: Seventy-eight patients were prospectively assigned to either the zolpidem group (multimodal analgesia+zolpidem; 39 patients) or the control group (multimodal analgesia; 39 patients). Self-rated pain levels were assessed twice a day using a visual analog scale (VAS). The need for additional rescue analgesic, duration of functional recovery, and adverse effects were assessed for the first 5 days after surgery. RESULTS: The mean number of times that additional rescue analgesic was required during 5 days after surgery was 2.1+/-2.0 in the zolpidem group and 3.3+/-2.8 in the control group, a significant difference. There were no significant differences between the two groups in mean VAS pain scores during the first 5 days after surgery, although the zolpidem group had lower VAS pain scores than the control group. Additionally, there were no significant differences in duration of functional recovery and adverse effects between the two groups. CONCLUSION: The use of zolpidem for analgesia after arthroscopic rotator cuff repair provided a significant reduction in the need for rescue analgesic without increasing adverse effects. Nevertheless, mean VAS pain scores during the first 5 days after surgery did not differ between the zolpidem group and the control group.
Adult
;
Analgesia/*methods
;
Analgesics/*therapeutic use
;
Arthroscopy/*adverse effects
;
Female
;
Humans
;
Hypnotics and Sedatives/*therapeutic use
;
Male
;
Middle Aged
;
Pain Management
;
Pain Measurement
;
Pain, Postoperative/drug therapy/etiology/*prevention & control
;
Postoperative Period
;
Prospective Studies
;
Pyridines/*therapeutic use
;
Rotator Cuff/injuries/*surgery
;
Sleep/drug effects
;
Treatment Outcome
;
Visual Analog Scale
7.Effects of Dexmedetomidine Infusion on the Recovery Profiles of Patients Undergoing Transurethral Resection.
So Young KWON ; Jin Deok JOO ; Ga Young CHEON ; Hyun Seok OH ; Jang Hyeok IN
Journal of Korean Medical Science 2016;31(1):125-130
Transurethral resection has been the gold standard in the operative management of benign prostatic hyperplasia and bladder tumor; however, it is associated with several complications that may cause patient discomfort. We evaluated the usefulness of continuous infusion of dexmedetomidine on emergence agitation, hemodynamic status, and recovery profiles in patients undergoing elective surgery by a randomized clinical trial. Sixty patients aged 30 to 80 yr who were scheduled for elective transurethral resection under general anesthesia were included in this study. Participants were randomly assigned to two groups (control group, group C; dexmedetomidine group, group D). A total of 60 male patients were enrolled in this study and randomly assigned to group C (n=30) or group D (n=30). The quality of emergence in group D was marked by a significantly lower incidence of emergence agitation than in group C (P=0.015). Patients in group D therefore felt less discomfort induced by the indwelling Foley catheter than those in group C (P=0.022). No statistically significant differences were found between the two groups with respect to side effects including bradycardia (P=0.085), hypotension (P=0.640), and postoperative nausea and vomiting (P=0.389). Our study showed that intraoperative dexmedetomidine infusion effectively reduced the incidence and intensity of emergence agitation and catheter-induced bladder discomfort without delaying recovery time and discharge time, thus providing smooth emergence during the recovery period in patients undergoing transurethral resection (Clinical Trial Registry No. KT0001683).
Adult
;
Aged
;
Aged, 80 and over
;
Blood Pressure
;
Bradycardia/etiology
;
Dexmedetomidine/adverse effects/*therapeutic use
;
Hemodynamics
;
Humans
;
Hypnotics and Sedatives/adverse effects/*therapeutic use
;
Hypotension/etiology
;
Male
;
Middle Aged
;
Nausea/etiology
;
Prostatic Hyperplasia/*surgery
;
Psychomotor Agitation/*drug therapy
;
*Transurethral Resection of Prostate
;
Vomiting/etiology